0000000000125027

AUTHOR

Andrea Santamaría

showing 1 related works from this author

Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer

2021

The combination of trastuzumab plus pertuzumab plus docetaxel as a first-line therapy in patients with HER2-positive metastatic breast cancer has provided significant clinical benefits compared to trastuzumab plus docetaxel alone. However, despite the therapeutic success of existing therapies targeting HER2, tumours invariably relapse. Therefore, there is an urgent need to improve our understanding of the mechanisms governing resistance, so that specific therapeutic strategies can be developed to provide improved efficacy. It is well known that the tumour microenvironment (TME) has a significant impact on cancer behaviour. Cancer-associated fibroblasts (CAFs) are essential components of the…

Receptor ErbB-2Cancer-associated fibroblastQH301-705.5breast cancer; HER2-positive; tumour microenvironment; targeted therapy; trastuzumab; resistance; cancer-associated fibroblast; label-free proteomics; miRNABreast NeoplasmsDocetaxelAntibodies Monoclonal HumanizedArticleCatalysisInorganic ChemistryresistanceDrug Delivery SystemsLabel-free proteomicsbreast cancerCancer-Associated FibroblastsCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsHumansPhysical and Theoretical ChemistryBiology (General)skin and connective tissue diseasesMolecular BiologyQD1-999SpectroscopymiRNAOrganic ChemistryGeneral Medicinetargeted therapyHER2-positiveComputer Science ApplicationstrastuzumabChemistryDrug Resistance NeoplasmFemaletumour microenvironmentInternational Journal of Molecular Sciences
researchProduct